Tuesday, 1 March 2016

Summit Therapeutics Supports Ninth Annual Rare Disease Day - NASDAQ.com

Summit Therapeutics Supports Ninth Annual Rare Disease Day - NASDAQ.com: "OXFORD, UK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD') and Clostridium difficile infection, announces today its support for the ninth annual Rare Disease Day on 29 February 2016. The Rare Disease Day 2016 theme, Patient Voice, recognises the crucial role that patients play in voicing their needs and in initiating change that improves their lives and the lives of their families and carers.

"On this ninth annual Rare Disease Day, we at Summit take this opportunity to pay tribute to all patients and their families living with rare diseases," commented Glyn Edwards, Chief Executive Officer of Summit Therapeutics.  "The patient and parent voice is playing a vital role in the development of our utrophin modulator therapies that offer the potential to treat all boys and men living with the rare disease, DMD, and Summit has an unwavering commitment towards bringing hope for all those affected by this disease.""

'via Blog this'

No comments:

Post a Comment